GIOTRIF® : The 1st choice in 1st-line

GIOTRIF® :
The 1st choice in 1st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
 
UNCOMMON EGFR MUTATIONS DATABASE Click here to access
 

Results from RealGiDo, a global real world study

Document ID: PC-MY-102827

03/02/2023

Author: Boehringer Ingelheim

123,000
Views

100k 340

RELATED CONTENT

 
PC-MY-102827
Production date: february 2023